SAFC Biosciences - - BioPharm International

ADVERTISEMENT

SAFC Biosciences

BioPharm International
Volume 18, Issue 12

Company Description



SAFC Biosciences is changing the very nature of bioscience. Combining excellent service with world-class science, SAFC Biosciences has developed a way to help biopharmaceutical companies bring products to market faster and accelerate their commercial success.

SAFC Biosciences develops, manufactures and markets cell culture reagents, specialty chemicals, downstream processing buffers and biodisposables to organizations involved in developing and producing biopharmaceuticals. It ensures regulatory compliance of its products through strict application to current Good Manufacturing Practice (cGMP) and ISO quality systems.

SAFC Biosciences is emerging as the new global leader in the cell culture market. With the power to respond to clients' developmental requirements faster, SAFC Biosciences does not just deliver ordinary bioscience, but bioscience beyond imagination.

Facilities

As a global organization, SAFC Biosciences has manufacturing and distribution facilities located in Kansas, Missouri, Pennsylvania, and Illinois in the United States, in Hampshire, England, Irvine, Scotland, and in Victoria, Australia. Numerous distributors are also established throughout Asia Pacific. With such global coverage, no single organization is better placed on the worldwide stage to deliver superior service and cost value.

The headquarters of SAFC Biosciences' parent company, Sigma-Aldrich, is located in St. Louis, MS, USA and is traded on NASDAQ. Sigma is a leading life sciences and high technology company marketing biochemical and organic chemical products and kits used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease, and as key components in pharmaceutical and other high technology manufacturing. It has customers in life sciences companies, university and government institutions, hospitals, and in industry. Sigma-Aldrich operates in 35 countries and has over 6,800 employees providing excellent service worldwide.

Products

  • EX-CELL Serum-Free Media specifically developed for the long-term growth of cells and expression of antibodies or protein products in suspension, adherent or stationary cultures.
  • Classical Media formulations for mammalian, insect, and plant cell culture are available in up to 12,500 liter lots of liquid media and up to 6,000 kg lots of dry powder media.
  • Sera including fetal bovine, calf, bovine, equine, and porcine serum, sourced in Australia, New Zealand and the USA, and filtered in USA and Australia in lot sizes up to 2,000 liters.
  • Growth Factors including LONGR3 IGF-I.
  • Specialty Products such as buffers, trypsin, protein components, reagents, and supplements.

Custom Products and Services

  • imMEDIAte ADVANTAGE Small Volume Media Program with quick turnaround and proven scale-up capabilities for customized cell culture media in both liquid (up to 200 liters) and dry powder (up to 100 L or 5 kg) formats, packaged in either bottles or bags.
  • BIOEAZE Disposable Bags and Bioprocessing Systems providing standard and application-specific systems including sterile bioprocess bags, rigging sets, tubing, tank liners and other components.
  • Media Development and Optimization programs to assist clients from early process development through production scale by meeting customer-specific requirements such as cell lines, targets of interest, time frames and regulatory needs.
  • Bulk Media Packaging specifically designed to meet customer-defined volumes, packaging and testing requirements providing maximum flexibility, and ease of use.
  • SER-TAIN Gamma Irradiation validated inactivation treatment providing an additional measure of safety to animal-derived material.
  • Technical Support concentrating on three areas of support – regulatory, customer, and product.

SAFC BIOSCIENCES
13804 W. 107th Street Lenexa, KS 66215

TELEPHONE
913.469.5580

FAX
913.469.5584

E-MAIL

WEB ADDRESS
http://www.safcbiosciences.com/

EMPLOYEES
600

FOUNDED
1971

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm International,
Click here